Information Provided By:
Fly News Breaks for September 15, 2015
RPTP
Sep 15, 2015 | 06:26 EDT
Citi analyst Joel Beatty downgraded Raptor Pharmaceuticals to Neutral after the Phase 2b trial of RP103 for pediatric fatty liver disease did not meet its primary endpoint. Beatty sees "stronger support" for RP103 in Huntington's disease, but believes an additional trial will be needed, pushing out approval to 2020. The analyst cut his price target for shares to $8 from $20. Shares of Raptor closed yesterday down $4.51 to $7.52.
News For RPTP From the Last 2 Days
There are no results for your query RPTP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.